Fresh capital injection for the Swiss medtech startup pregnolia
scroll south
Congratulations to our Venture Leaders Life Sciences, TOP100 startup and Venture Kick alumnus who has raised an early stage investment
Pregnolia, the Swiss medtech company and ETH Zurich spin-off, has successfully announced the closing of a CHF 3.25 million seed round investment with investiere.ch, Zürcher Kantonalbank and the investment department of CADFEM.Pursuing the goal of predicting the risk of premature birth, the company has gone through our support programs and joined the Venture Leaders Life Science in Boston with the Swiss National Startup Team in 2016. The same year, Pregnolia won the third stage of Venture Kick and received CHF 130,000 as well as mentoring support. Moreover, Pregnolia was featured in the TOP 100 Swiss startups ranking in 2016 and 2017.
About Pregnolia
Pregnolia is a women’s health medtech company, developing a diagnostic device to accurately predict the risk of premature birth during routine pregnancy consultation. Early diagnosis enables preventive intervention to prolong gestation and improve neonatal health outcome. Pregnolia’s proprietary technology addresses both the health and economic challenges of preterm birth.
